PMID- 27081877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 140
IP  - 11
DP  - 2016 Nov
TI  - Assessing the New American Society of Clinical Oncology/College of American 
      Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: 
      Experience of an Academic Consultation Practice.
PG  - 1250-1258
AB  - Context .- Evaluation of HER2 gene amplification by fluorescence in situ 
      hybridization (FISH) was changed by recent American Society of Clinical 
      Oncology/College of American Pathologists (ASCO-CAP) guidelines. Objective . -To 
      determine frequencies and assess patterns of HER2 protein expression for each 
      ASCO-CAP guideline FISH category among 7526 breast cancers accrued to our 
      consultation practice. Design .- We retrospectively reevaluated the HER2 FISH 
      status of breast cancers in our consultation practice according to ASCO-CAP FISH 
      guidelines, and documented HER2 protein levels in each category. Results . 
      -According to new guidelines, 17.7% of our consultation breast cancers were 
      "ISH-positive" with HER2:CEP17 FISH ratios >/=2.0 and average HER2 gene copies per 
      cell >/=4.0 (group 1); 0.4% were "ISH-positive" with ratios >/=2.0 and average copies 
      <4.0 (group 2); 0.6% were "ISH-positive" with ratios <2.0 and average copies >/=6.0 
      (group 3); 4.6% were "ISH-equivocal" with ratios <2.0 and average copies >/=4.0 and 
      <6.0 (group 4); and 76.7% were "ISH-negative" with ratios <2.0 and average copies 
      <4.0 (group 5). However, only groups 1 (HER2 amplified) and 5 (HER2 not 
      amplified) agreed with our previously reported status, and only these groups 
      demonstrated the expected immunohistochemistry status, overexpression and low 
      expression, respectively. Groups 2 and 4 breast cancers lacked overexpression, 
      whereas group 3 was not significantly associated with either increased or 
      decreased HER2 expression. Conclusions .- Although the status of approximately 
      95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of 
      the other 5% (groups 2-4) conflict with previous HER2 gene amplification status 
      and with HER2 status by immunohistochemistry.
FAU - Press, Michael F
AU  - Press MF
FAU - Villalobos, Ivonne
AU  - Villalobos I
FAU - Santiago, Angela
AU  - Santiago A
FAU - Guzman, Roberta
AU  - Guzman R
FAU - Cervantes, Monica
AU  - Cervantes M
FAU - Gasparyan, Armen
AU  - Gasparyan A
FAU - Campeau, Anaamika
AU  - Campeau A
FAU - Ma, Yanling
AU  - Ma Y
FAU - Tsao-Wei, Denice D
AU  - Tsao-Wei DD
FAU - Groshen, Susan
AU  - Groshen S
AD  - From the Departments of Pathology (Drs Press and Ma; Mss Villalobos, Santiago, 
      Guzman, Cervantes, and Campeau; and Mr Gasparyan) and Preventive Medicine (Ms 
      Tsao-Wei and Dr Groshen), Norris Comprehensive Cancer Center, University of 
      Southern California, Los Angeles.
LA  - eng
GR  - P30 CA014089/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160415
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
PMC - PMC9022709
MID - NIHMS1622216
EDAT- 2016/04/16 06:00
MHDA- 2016/04/16 06:01
PMCR- 2022/04/21
CRDT- 2016/04/16 06:00
PHST- 2016/04/16 06:00 [entrez]
PHST- 2016/04/16 06:00 [pubmed]
PHST- 2016/04/16 06:01 [medline]
PHST- 2022/04/21 00:00 [pmc-release]
AID - 10.5858/arpa.2016-0009-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2016 Nov;140(11):1250-1258. doi: 10.5858/arpa.2016-0009-OA. 
      Epub 2016 Apr 15.